Ocrelizumab
- Generic Name
- Ocrelizumab
- Brand Names
- Ocrevus
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 637334-45-3
- Unique Ingredient Identifier
- A10SJL62JY
- Background
Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-humanized CD20 antibodies such as rituximab, ...
- Indication
用于治疗复发型多发性硬化症（MS）。
- Associated Conditions
- Clinically Isolated Syndrome (CIS), Primary Progressive Multiple Sclerosis (PPMS), Relapsing Multiple Sclerosis (RMS), Relapsing Remitting Multiple Sclerosis (RRMS), Active Secondary Progressive Multiple Sclerosis (SPMS)
- Associated Therapies
- -
Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease
- Conditions
- Interventions
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Haukeland University Hospital
- Target Recruit Count
- 214
- Registration Number
- NCT04578639
- Locations
- 🇳🇴
Haukeland University Hospital, Bergen, Norway
🇳🇴Nordlandsykehuset HF, Bodø, Norway
🇳🇴Molde sjukehus, Molde, Norway
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
- Conditions
- Interventions
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 769
- Registration Number
- NCT04548999
- Locations
- 🇺🇸
University of California Irvine, Irvine, California, United States
🇺🇸Massachusetts General Hospital., Boston, Massachusetts, United States
🇵🇱Neurologiczny Niepubliczny ZOZ Centrum Leczenia SM Osrodek Bada? Klinicznych, Plewiska, Poland
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
- Conditions
- Interventions
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 864
- Registration Number
- NCT04544436
- Locations
- 🇺🇸
Maine Medical Center, Scarborough, Maine, United States
🇵🇱Neurocentrum Bydgoszcz sp. z o.o, Bydgoszcz, Poland
🇵🇱Indywidualna Praktyka Lekarska Prof. Dr Hab. N. Med. Konrad Rejdak., Lublin, Poland
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 985
- Registration Number
- NCT04544449
- Locations
- 🇦🇷
Focus CECIC, Buenos Aires, Argentina
🇺🇸Alabama Neurology Associates, Homewood, Alabama, United States
🇺🇸Sutter East Bay Medical Foundation, Berkeley, California, United States
Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset
- Conditions
- Interventions
- First Posted Date
- 2020-07-10
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 30
- Registration Number
- NCT04466150
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
Mechanistic Study of Ocrevus
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 35
- Registration Number
- NCT04459988
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Effects of Ocrevus in Relapsing Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2020-05-14
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Georgia State University
- Target Recruit Count
- 60
- Registration Number
- NCT04387734
- Locations
- 🇺🇸
Multiple Sclerosis Center of Atlanta, Atlanta, Georgia, United States
🇺🇸Georgia State University, Atlanta, Georgia, United States
Ocrelizumab in Breastmilk
- First Posted Date
- 2020-05-13
- Last Posted Date
- 2022-12-16
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 30
- Registration Number
- NCT04387110
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab.
- First Posted Date
- 2020-05-06
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 179
- Registration Number
- NCT04377555
- Locations
- 🇺🇸
Shepherd Center Inc., Atlanta, Georgia, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸SUNY Upstate Medical University, Syracuse, New York, United States
Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 10
- Registration Number
- NCT04261790
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.